© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 15th 2021, 5:37pm
Ilumya (tildrakizumab) was shown to be safe and effective in controlling moderate to severe psoriasis for adults through 5 years of treatment in a recent study.
June 30th 2020, 8:31pm
A Taiwanese study revealed that attributes associated with polycystic ovary syndrome (PCOS) may increase the risks of those patients developing psoriasis as well.
June 30th 2020, 2:42am
A study analyzing patients with psoriasis revealed that personality traits may have a greater impact on the development of social anxiety than disease severity.
June 20th 2020, 8:22pm
The impact of psoriatic arthritis on quality of life can vary depending on geographic location and culture, according to a global patient survey.
June 19th 2020, 11:01pm
In 90% of patients, psoriasis precedes psoriatic arthritis by an average of 7 years, providing a window of opportunity for early intervention and possible prevention of psoriatic arthritis.
June 13th 2020, 2:00pm
Authors of an opinion piece concluded that not only are immunosuppressed patients with psoriasis not at an increased risk of developing serious complications related to coronavirus disease 2019 (COVID-19), their medications may help mitigate potential issues.
June 12th 2020, 1:06am
Patients with psoriasis often have other physical diseases, and these somatic comorbidities can have a bigger effect on the patient’s mental health than the skin symptoms from their psoriasis, according to a study published in JAMA Dermatology.
June 5th 2020, 9:57pm
The study looked at patients taking ixekizumab or adalimumab.
June 3rd 2020, 5:00pm
A global epidemiological study on psoriasis has found that the prevalence, incidence, and burden of suffering caused by the disease has risen over the last 3 decades.
May 30th 2020, 7:00pm
Use of biologics to treat psoriasis may impact prevalence of comorbidities like depression and obesity, according to an abstract presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research meeting.